Truist Lowers PT on Vericel Corporation (VCEL) to $41 From $46

Vericel Corporation (NASDAQ:VCEL) is one of the best small cap stocks with the highest upside. On October 15, Truist lowered the price target on Vericel Corporation (NASDAQ:VCEL) to $41 from $46 while keeping a Buy rating on the shares. The rating update was released as part of a broader research note that previewed Q3 results in MedTech.

Vericel Corporation (VCEL): Among Stocks with Insanely High PE Ratios Insiders Are Selling

The firm told investors that while it anticipates “healthy” Q3 revenue and earnings across its coverage, it is also bracing for “stock volatility”, with new money feeling absent from the space.

Truist further stated that, like Q2, fund and specialist positioning may result in excessive reactions on anything counter to crowded positioning, which is why it is tilting towards “cleaner” names that have less perceived controversy going into the quarter.

Vericel Corporation (NASDAQ:VCEL) is involved in product development, research, manufacturing, and distribution of patient-specific, expanded cellular therapies that help treat diseases. The company’s product portfolio includes Epicel and MACI.

Epicel covers skin replacement for patients with deep dermal or full-thickness burns, while the MACI portfolio is FDA-approved for the process of tissue engineering for cell growth on scaffolds using healthy cartilage tissue derived from the patient’s own knee.

While we acknowledge the potential of VCEL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VCEL and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.